Erlotinib nearly triples progression-free survival compared with standard chemotherapy in patients with the most common form of lung cancer (OPTIMAL trial)

July 21, 2011

The targeted drug erlotinib nearly triples progression-free survival (PFS), and is better tolerated, compared with standard chemotherapy as the initial treatment for patients with advanced non-small-cell lung cancer (NSCLC) whose tumours harbour epidermal growth factor receptor (EGFR) mutations. The results, published Online First in The Lancet Oncology, suggest that erlotinib should be one of the first-line treatments now considered for advanced NSCLC in patients with activating EGFR mutations.

Despite progress in recent years, lung cancer remains the leading cause of cancer death worldwide. Increasingly, research has focused on identifying potential biomarkers to prolong survival from new targeted drugs and optimise treatment decisions for individual patients. To date, the most promising of these markers is EGFR mutation status. Previous studies have shown that NSCLC patients with EGFR mutations respond well to tyrosine kinase inhibitor (TKI) therapies such as erlotinib.

The OPTIMAL study is the first phase 3 trial to examine whether erlotinib has comparable efficacy and safety to chemotherapy in patients whose lung cancer harbours EGFR mutations. 165 patients were recruited from 22 centres across China and randomly assigned to erlotinib (83 patients) or a standard platinum chemotherapy regimen of gemcitabine and carboplatin (82).

Erlotinib significantly prolonged median PFS compared with chemotherapy (13.1 months vs 4.6 months).

Serious treatment-related side-effects were only reported in 2% of patients treated with erlotinib compared with 14% given chemotherapy. Grade 3 and 4 toxic effects were also more common in patients receiving chemotherapy, with 42% of patients experiencing neutropenia (low white blood count) and 40% thrombocytopenia (abnormally low number of platelets in the blood) compared with no patients taking erlotinib. The most frequently reported grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concentrations (4%) and skin rash (2%).

The authors say: "To our knowledge, OPTIMAL is the first phase 3 study to show that patients with EGFR mutation-positive NSCLC who receive erlotinib can live for more than a year without disease progression and also clearly shows the clinical usefulness of testing for a molecular biomarker in lung cancer to guide treatment and improve patient outcomes."

They conclude: "We recommend that EGFR TKIs be regarded as the first-line treatment of choice for this subgroup of patients and chemonaive patients should undergo EGFR mutation testing wherever possible."

In a Comment, Tetsuya Mitsudomi from Aichi Cancer Center Hospital, Nagoya, Japan says: "OPTIMAL clearly shows the importance of EGFR mutation testing and patient selection according to these test results for use of erlotinib...EGFR TKIs are undoubtedly key drugs for patients with EGFR mutations and should be used early in treatment. However, when EGFR test results cannot be obtained in a reasonably short timeframe, first-line chemotherapy and second-line EGFR TKI after progression is a reasonable option if the patient is later shown to be EGFR mutation-positive."
Professor Caicun Zhou, Tongji University, Shanghai, China. T) +86 21 6511 5006-3051 (office) or +86 13301825532 (mobile) E)

Dr Tetsuya Mitsudomi, Aichi Cancer Center Hospital, Nagoya, Japan. T) +81 52 762 6111 E)

Notes to Editors: *Quotes direct from authors and cannot be found in text of Article


Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to